Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA.
作者信息
Della Corte C M, Morgillo F
机构信息
Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania 'Luigi Vanvitelli', Naples, Italy.
Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania 'Luigi Vanvitelli', Naples, Italy.
出版信息
ESMO Open. 2021 Feb;6(1):100041. doi: 10.1016/j.esmoop.2020.100041. Epub 2021 Jan 18.
Abstract
摘要
相似文献
1
Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA.重新思考RET基因改变的肺癌和甲状腺癌的治疗：selpercatinib获欧洲药品管理局批准
ESMO Open. 2021 Feb;6(1):100041. doi: 10.1016/j.esmoop.2020.100041. Epub 2021 Jan 18.
2
Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.塞尔帕替尼用于治疗具有RET基因突变或融合的肺癌和甲状腺癌。
Drugs Today (Barc). 2021 Oct;57(10):621-629. doi: 10.1358/dot.2021.57.10.3313852.
3
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers.术前使用塞尔帕替尼治疗RET基因改变的甲状腺癌
Ann Surg Oncol. 2024 Apr;31(4):2202-2203. doi: 10.1245/s10434-023-14854-w. Epub 2024 Jan 20.
4
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.针对非肺或甲状腺肿瘤的 RET 融合阳性实体瘤患者，塞普替尼的肿瘤不可知疗效和安全性（LIBRETTO-001）：一项 1/2 期、开放标签、篮子试验。
Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: 10.1016/S1470-2045(22)00541-1. Epub 2022 Sep 12.
5
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with Gene Mutations or Fusions.FDA 批准概要：塞普替尼用于治疗具有基因突变或融合的肺癌和甲状腺癌。
Clin Cancer Res. 2021 Apr 15;27(8):2130-2135. doi: 10.1158/1078-0432.CCR-20-3558. Epub 2020 Nov 25.
6
Selpercatinib: First Approval.塞尔帕替尼：首次批准。
Drugs. 2020 Jul;80(11):1119-1124. doi: 10.1007/s40265-020-01343-7.
7
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.非关键 RET 突变介导的获得性对塞尔帕替尼和普拉替尼耐药的结构基础。
Ann Oncol. 2021 Feb;32(2):261-268. doi: 10.1016/j.annonc.2020.10.599. Epub 2020 Nov 5.
8
Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.塞尔帕替尼用于治疗局部晚期或转移性RET基因改变的实体瘤成年患者。
Expert Rev Anticancer Ther. 2023 Jul-Dec;23(11):1117-1122. doi: 10.1080/14737140.2023.2267754. Epub 2023 Oct 27.
9
Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma.在RET改变的甲状腺癌中进行治疗前剂量估计后，塞普替尼与放射性碘的成功联合应用。
Eur J Nucl Med Mol Imaging. 2023 May;50(6):1833-1834. doi: 10.1007/s00259-022-06061-8. Epub 2022 Dec 16.
10
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.通过塞普替尼联合克唑替尼克服 RET 融合阳性肺癌患者对选择性 RET 抑制的 MET 依赖性耐药。
Clin Cancer Res. 2021 Jan 1;27(1):34-42. doi: 10.1158/1078-0432.CCR-20-2278. Epub 2020 Oct 20.
引用本文的文献
1
Systemic Therapeutic Options in Radioiodine-Refractory Differentiated Thyroid Cancer: Current Indications and Optimal Timing.放射性碘难治性分化型甲状腺癌的全身治疗选择：当前适应症和最佳时机
Cancers (Basel). 2025 May 28;17(11):1800. doi: 10.3390/cancers17111800.
2
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer.RET抑制克服了雌激素受体阳性乳腺癌对CDK4/6抑制剂与内分泌治疗联合方案的耐药性。
Front Oncol. 2025 Jan 27;14:1497093. doi: 10.3389/fonc.2024.1497093. eCollection 2024.
3
Selpercatinib in Chinese patients with -fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the randomized LIBRETTO-321 phase II trial.塞尔帕替尼治疗中国 -融合阳性非小细胞肺癌患者：随机II期LIBRETTO-321试验的疗效和安全性更新分析
Ther Adv Med Oncol. 2025 Jan 1;17:17588359241307199. doi: 10.1177/17588359241307199. eCollection 2025.
4
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.分子遗传学、治疗学和 RET 抑制剂耐药性在甲状腺髓样癌中的应用及未来展望。
Cell Commun Signal. 2024 Sep 28;22(1):460. doi: 10.1186/s12964-024-01837-x.
5
Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study.RET基因改变的甲状腺癌患者护理中的挑战：一项多国混合方法研究。
Thyroid Res. 2023 Aug 14;16(1):22. doi: 10.1186/s13044-023-00166-4.
6
A comprehensive overview of the relationship between RET gene and tumor occurrence.RET基因与肿瘤发生关系的全面概述。
Front Oncol. 2023 Feb 14;13:1090757. doi: 10.3389/fonc.2023.1090757. eCollection 2023.
7
Targeted therapy of RET fusion-positive non-small cell lung cancer.RET融合阳性非小细胞肺癌的靶向治疗
Front Oncol. 2022 Dec 13;12:1033484. doi: 10.3389/fonc.2022.1033484. eCollection 2022.
8
RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.RET原癌基因——并非癌症治疗中一个显而易见的起点。
Cancers (Basel). 2022 Oct 27;14(21):5298. doi: 10.3390/cancers14215298.
9
Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment.非小细胞肺癌小标本生物标志物检测专家意见 - 第 2 部分：分析、报告和质量评估。
Virchows Arch. 2022 Sep;481(3):351-366. doi: 10.1007/s00428-022-03344-1. Epub 2022 Jul 20.
10
Research Progress on RET Fusion in Non-Small-Cell Lung Cancer.非小细胞肺癌中RET融合的研究进展
Front Oncol. 2022 May 30;12:894214. doi: 10.3389/fonc.2022.894214. eCollection 2022.
本文引用的文献
1
Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.塞尔帕替尼用于治疗具有RET基因突变或融合的肺癌和甲状腺癌。
Drugs Today (Barc). 2021 Oct;57(10):621-629. doi: 10.1358/dot.2021.57.10.3313852.
2
Efficacy of Selpercatinib in -Altered Thyroid Cancers.塞尔帕替尼在改变的甲状腺癌中的疗效。
N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651.
3
Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer.塞尔帕替尼治疗融合阳性非小细胞肺癌的疗效
N Engl J Med. 2020 Aug 27;383(9):813-824. doi: 10.1056/NEJMoa2005653.
4
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.卡博替尼用于晚期RET重排非小细胞肺癌患者：一项开放标签、单中心、2期、单臂试验。
Lancet Oncol. 2016 Dec;17(12):1653-1660. doi: 10.1016/S1470-2045(16)30562-9. Epub 2016 Nov 4.
5
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.凡德他尼治疗经治 RET 重排的晚期非小细胞肺癌患者（LURET）：一项开放标签、多中心 2 期临床试验。
Lancet Respir Med. 2017 Jan;5(1):42-50. doi: 10.1016/S2213-2600(16)30322-8. Epub 2016 Nov 4.
6
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.凡德他尼治疗经治的晚期非小细胞肺癌伴 RET 重排患者：一项 II 期临床试验。
Ann Oncol. 2017 Feb 1;28(2):292-297. doi: 10.1093/annonc/mdw559.
7
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.乐伐替尼对比安慰剂用于碘难治性甲状腺癌。
N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470.
8
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.索拉非尼用于放射性碘难治性、局部晚期或转移性分化型甲状腺癌：一项随机、双盲、3期试验。
Lancet. 2014 Jul 26;384(9940):319-28. doi: 10.1016/S0140-6736(14)60421-9. Epub 2014 Apr 24.
9
Cabozantinib in progressive medullary thyroid cancer.卡博替尼治疗进展性甲状腺髓样癌。
J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3.
10
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.凡德他尼治疗局部晚期或转移性甲状腺髓样癌患者的疗效：一项随机、双盲 III 期临床试验。
J Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24.
Zotero 插件